Cystic Fibrosis Foundation issued the following clinical trial alerts on June 14th:
Status: Enrolling
Description: This study will look at the effectiveness of Trikafta®, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older who have two CFTR mutations not approved for Trikafta® and evidence of partial CFTR function. Partial function is defined as a sweat chloride level < 80 mmol/L and/or pancreatic sufficiency (no pancreatic enzyme supplement therapy).
Age: 12 Years and Older
Mutation: No Copies F508del
Fev1% Predicted: No FEV1 Limit
Number of Visits: 5
Length of Participation: 2 months
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03506061
Study of Trikafta® in people with CF ages 12 years and older who have an N1303K CFTR mutation
Status: Enrolling
Description: This study will look at the effectiveness of Trikafta, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older who have two CFTR mutations not approved for Trikafta® and a least one of these mutations must be N1303K.
Age: 12 Years and Older
Mutation: No Copies F508del
Fev1% Predicted: No FEV1 Limit
Number of Visits: 5
Length of Participation: 86 days
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03506061